Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surotomycin in Clostridium Difficile Associated Diarrhea
NCT01598311Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2012
- Primary completion
- Jul 2015
- Modality
- Cyclic Peptides, Peptide Conjugates, Antimicrobial Peptides
01
Overview
A Phase 3 trial of surotomycin in Clostridium difficile infection (CDI), sponsored by Merck & Co.. Started May 2012; status: completed.
02
Drugs
surotomycin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT01598311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01598311.